Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHA NASDAQ:BTAI NASDAQ:CLNN NASDAQ:CUE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$0.36-5.5%$0.40$0.22▼$0.83$14.67M3.01333,133 shs507,346 shsBTAIBioXcel Therapeutics$3.16-6.9%$3.30$1.17▼$13.36$50.75M0.25.16 million shs2.34 million shsCLNNClene$5.95-3.7%$4.44$2.28▼$7.10$59.38M0.5877,797 shs90,361 shsCUECue Biopharma$0.74-3.0%$0.80$0.45▼$1.99$57.33M1.58247,209 shs352,444 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma+0.29%-1.27%-0.70%+25.69%-22.02%BTAIBioXcel Therapeutics-3.69%-5.04%-50.15%+117.31%-61.41%CLNNClene-4.48%+3.87%+67.03%+50.73%+1.48%CUECue Biopharma+0.49%-2.46%-3.08%+27.19%+29.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$0.36-5.5%$0.40$0.22▼$0.83$14.67M3.01333,133 shs507,346 shsBTAIBioXcel Therapeutics$3.16-6.9%$3.30$1.17▼$13.36$50.75M0.25.16 million shs2.34 million shsCLNNClene$5.95-3.7%$4.44$2.28▼$7.10$59.38M0.5877,797 shs90,361 shsCUECue Biopharma$0.74-3.0%$0.80$0.45▼$1.99$57.33M1.58247,209 shs352,444 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma+0.29%-1.27%-0.70%+25.69%-22.02%BTAIBioXcel Therapeutics-3.69%-5.04%-50.15%+117.31%-61.41%CLNNClene-4.48%+3.87%+67.03%+50.73%+1.48%CUECue Biopharma+0.49%-2.46%-3.08%+27.19%+29.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHAAthira Pharma 2.00Hold$0.5030.21% UpsideBTAIBioXcel Therapeutics 2.67Moderate Buy$39.751,148.04% UpsideCLNNClene 3.00Buy$32.60461.58% UpsideCUECue Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATHA, BTAI, CLNN, and CUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $31.008/28/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/26/2025BTAIBioXcel TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/21/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.008/18/2025CLNNCleneCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$83.00 ➝ $48.008/15/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.008/14/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.007/18/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.006/30/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/ABTAIBioXcel Therapeutics$2.27M22.46N/AN/A($30.01) per share-0.11CLNNClene$340K171.25N/AN/A($1.06) per share-5.48CUECue Biopharma$9.29M6.25N/AN/A$0.28 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHAAthira Pharma-$96.94M-$1.55N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)BTAIBioXcel Therapeutics-$59.60M-$12.64N/AN/AN/A-5,869.82%N/A-134.45%11/13/2025 (Estimated)CLNNClene-$39.40M-$3.76N/AN/AN/A-10,386.36%N/A-125.49%11/12/2025 (Estimated)CUECue Biopharma-$40.67M-$0.56N/AN/AN/A-469.35%-230.13%-111.16%11/13/2025 (Estimated)Latest ATHA, BTAI, CLNN, and CUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLNNClene-$0.49-$0.78-$0.29-$0.78$0.06 million$0.03 million8/12/2025Q2 2025BTAIBioXcel Therapeutics-$2.30-$2.45-$0.15-$2.45$0.21 million$0.12 million8/12/2025Q2 2025CUECue Biopharma-$0.13-$0.09+$0.04-$0.09$2.00 million$2.95 million8/7/2025Q2 2025ATHAAthira Pharma-$0.18-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHAAthira PharmaN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHAAthira PharmaN/A10.8110.81BTAIBioXcel TherapeuticsN/A0.760.74CLNNCleneN/A1.581.57CUECue Biopharma0.011.601.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHAAthira Pharma57.12%BTAIBioXcel Therapeutics30.68%CLNNClene23.28%CUECue Biopharma35.04%Insider OwnershipCompanyInsider OwnershipATHAAthira Pharma22.10%BTAIBioXcel Therapeutics21.20%CLNNClene35.30%CUECue Biopharma10.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHAAthira Pharma4039.44 million30.72 millionOptionableBTAIBioXcel Therapeutics9016.01 million12.62 millionOptionableCLNNClene10010.03 million6.49 millionOptionableCUECue Biopharma6076.85 million68.56 millionOptionableATHA, BTAI, CLNN, and CUE HeadlinesRecent News About These CompaniesCue Biopharma (NASDAQ:CUE) Shares Down 1% - What's Next?September 7, 2025 | marketbeat.comLUCID CAPITAL MARKETS Initiates Coverage of Cue Biopharma (CUE) with Buy RecommendationAugust 26, 2025 | msn.comRecurrent or Metastatic Head and Neck cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and CompaniesAugust 25, 2025 | theglobeandmail.comCue Biopharma initiated with a Buy at Lucid CapitalAugust 25, 2025 | msn.comCue Biopharma to Present Program Updates at Cantor Global Healthcare Conference 2025August 21, 2025 | quiverquant.comQCue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare ConferenceAugust 21, 2025 | globenewswire.comCue Biopharma (NASDAQ:CUE) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPSAugust 15, 2025 | marketbeat.comCue Biopharma announces initiation of investigator sponsored trial of CUE-102August 13, 2025 | msn.comCue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent ...August 13, 2025 | bakersfield.comBCue Biopharma, Inc.: Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 13, 2025 | finanznachrichten.deCue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma MultiformeAugust 13, 2025 | finance.yahoo.comCue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma MultiformeAugust 13, 2025 | globenewswire.comCue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue EstimatesAugust 12, 2025 | zacks.comCue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 12, 2025 | globenewswire.comCue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing ...July 16, 2025 | bakersfield.comBCue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck CancerJuly 16, 2025 | globenewswire.comCue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on ... - The Manila TimesJuly 3, 2025 | manilatimes.netMCue Biopharma reports promising results for HPV+ head and neck cancer drug - Investing.comJuly 3, 2025 | investing.comCue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic ... - MorningstarJuly 3, 2025 | morningstar.comMCue Biopharma Amends License Agreement with MIL 40GJuly 1, 2025 | tipranks.comCue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic MalignanciesJuly 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNHBy Ryan Hasson | August 15, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 2025With Rate Cuts Ahead, Buffett-Backed Builders Look Like a BuyBy Jordan Chussler | September 4, 2025Constellation Lowers Outlook: Time to Panic on Buffett's Big Bet?By Leo Miller | September 12, 2025ATHA, BTAI, CLNN, and CUE Company DescriptionsAthira Pharma NASDAQ:ATHA$0.36 -0.02 (-5.52%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.BioXcel Therapeutics NASDAQ:BTAI$3.16 -0.24 (-6.93%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Clene NASDAQ:CLNN$5.95 -0.23 (-3.72%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Cue Biopharma NASDAQ:CUE$0.74 -0.02 (-2.96%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
